Autore/Fonte: www.Epac.it
Centri di riferimento HCV – UMBRIA
Leggi →
Dicembre 2022
Questo è quello che abbiamo trovato per te
Autore/Fonte: www.Epac.it
Autore/Fonte: www.Epac.it
Autore/Fonte: www.Epac.it
Autore/Fonte: www.Epac.it
Autore/Fonte: www.Epac.it
Autore/Fonte: www.Epac.it
Autore/Fonte: www.Epac.it
Autore/Fonte: www.Epac.it
Autore/Fonte: www.Epac.it
Autore/Fonte: www.Epac.it
Per professor Gammaitoni “anomalia”, diffusione sottostimata
Sono 143 quelli aderenti al progetto
Objectives
Dynamics of antibody responses following SARS-CoV-2 infection are controversial in terms of immunity and persistence. We aimed to assess longitudinally the trend of antibody serological titres, their correlation with clinical severity as well as clinical reinfection during a follow-up.
Design
Longitudinal cohort, 12 months follow-up study.
Setting
USL Umbria 2.
Participants
Consecutive subjects aged 15–75 who were discharged with the diagnosis of Sars-Cov-2 from the hospitals of the AUSL Umbria 2, or resulted positive to a PCR test for SARS-CoV-2 infection with or without symptoms were recruited. SARS-CoV-2 serological testing for antibodies targeting the Nucleocapside and Spike proteins were determined.
Results
Of 184 eligible subjects, 149 were available for evaluation: 17 were classified as oligo/asymptomatic, 107 as symptomatic, 25 as hospital admitted. Participants differed in terms of signs and symptoms as well as treatment. Overall there was a significant difference in terms of antibody titres between groups (anti-S: p
Autore/Fonte: Liver Int.
Autore/Fonte: A. Rossi, L.A. Kondili, M. Andreoni, F.P. Russo, S. Petta, I. Grattagliano, C. Cricelli
Autore/Fonte: Ignazio Grattagliano